These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35055389)

  • 1. Targeted Therapy in Leukaemia, Lymphoma and Myeloma.
    Opat SS
    J Pers Med; 2022 Jan; 12(1):. PubMed ID: 35055389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and pattern of liver involvement in haematological malignancies.
    Walz-Mattmüller R; Horny HP; Ruck P; Kaiserling E
    Pathol Res Pract; 1998; 194(11):781-9. PubMed ID: 9842637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
    Di Ciaccio P; McCaughan G; Trotman J; Ho PJ; Cheah CY; Gangatharan S; Wight J; Ku M; Quach H; Gasiorowski R; Polizzotto MN; Prince HM; Mulligan S; Tam CS; Gregory G; Hapgood G; Spencer A; Dickinson M; Latimer M; Johnston A; Armytage T; Lee C; Cochrane T; Berkhahn L; Weinkove R; Doocey R; Harrison SJ; Webber N; Lee HP; Chapman S; Campbell BA; Gibbs SDJ; Hamad N
    Intern Med J; 2020 Jun; 50(6):667-679. PubMed ID: 32415723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study.
    Leuraud K; Richardson DB; Cardis E; Daniels RD; Gillies M; O'Hagan JA; Hamra GB; Haylock R; Laurier D; Moissonnier M; Schubauer-Berigan MK; Thierry-Chef I; Kesminiene A
    Lancet Haematol; 2015 Jul; 2(7):e276-81. PubMed ID: 26436129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cancer registry-based study of occupational risk for lymphoma, multiple myeloma and leukaemia.
    Brownson RC; Reif JS
    Int J Epidemiol; 1988 Mar; 17(1):27-32. PubMed ID: 3384545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma, multiple myeloma and leukaemia among French farmers in relation to pesticide exposure.
    Viel JF; Richardson ST
    Soc Sci Med; 1993 Sep; 37(6):771-7. PubMed ID: 8211293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation.
    Sander B; Campo E; Hsi ED
    Virchows Arch; 2023 Jan; 482(1):131-145. PubMed ID: 36454275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological models for leukaemia and lymphoma.
    Greaves MF
    IARC Sci Publ; 2004; (157):351-72. PubMed ID: 15055306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary acute lymphoblastic leukaemia in a multiple myeloma patient.
    Piszcz J; Bolkun L; Cichocka E; Kloczko J
    Contemp Oncol (Pozn); 2012; 16(6):593-5. PubMed ID: 23788951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study.
    De Angelis R; Minicozzi P; Sant M; Dal Maso L; Brewster DH; Osca-Gelis G; Visser O; Maynadié M; Marcos-Gragera R; Troussard X; Agius D; Roazzi P; Meneghini E; Monnereau A;
    Eur J Cancer; 2015 Oct; 51(15):2254-2268. PubMed ID: 26421827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma.
    Howell DA; Warburton F; Ramirez AJ; Roman E; Smith AG; Forbes LJ
    Br J Cancer; 2015 Sep; 113(7):1114-20. PubMed ID: 26325101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INVESTIGATIONS OF THE IMMUNOLOGICAL REACTIVITY IN HAEMOBLASTOSES. II. BLOOD COMPLEMENT VALUES IN LEUKAEMIA, MALIGNANT LYMPHOMA, AND MYELOMA.
    LIBANSKY J; JEZKOVA Z
    Neoplasma; 1963; 10():605-19. PubMed ID: 14103648
    [No Abstract]   [Full Text] [Related]  

  • 13. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
    Sallman DA; Kerre T; Havelange V; Poiré X; Lewalle P; Wang ES; Brayer JB; Davila ML; Moors I; Machiels JP; Awada A; Alcantar-Orozco EM; Borissova R; Braun N; Dheur MS; Gilham DE; Lonez C; Lehmann FF; Flament A
    Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.
    Rømer FK; Emmertsen K
    Br J Cancer; 1980 Aug; 42(2):314-8. PubMed ID: 6252927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR).
    Lim KJ; Wellard C; Talaulikar D; Tan JL; Loh J; Puvanakumar P; Kuzich JA; Ho M; Murphy M; Zeglinas N; Low MS; Routledge D; Lim AB; Gibbs SD; Quach H; Morgan S; Moore E; Ninkovic S
    EJHaem; 2023 Aug; 4(3):639-646. PubMed ID: 37601874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.
    Abar L; Sobiecki JG; Cariolou M; Nanu N; Vieira AR; Stevens C; Aune D; Greenwood DC; Chan DSM; Norat T
    Ann Oncol; 2019 Apr; 30(4):528-541. PubMed ID: 30753270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
    Sant M; Minicozzi P; Mounier M; Anderson LA; Brenner H; Holleczek B; Marcos-Gragera R; Maynadié M; Monnereau A; Osca-Gelis G; Visser O; De Angelis R;
    Lancet Oncol; 2014 Aug; 15(9):931-42. PubMed ID: 25030467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
    Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
    Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MABS: targeted therapy tailored to the patient's need.
    El Miedany Y
    Br J Nurs; 2015 Sep; 24(16 Suppl 1):S4-13. PubMed ID: 26946646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.